Eli Lilly's Popular Weight Loss, Anti-Diabetes Drug Mounjaro Launched In India

Eli Lilly has launched the highly anticipated diabetes and obesity management drug Mounjaro (tirzepatide) in India following approval from the drug regulator. Priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial, Mounjaro is administered once a week. Depending on the prescribed dosage, the monthly cost ranges between Rs 14,000 and Rs 17,500. In comparison, the average monthly price of Mounjaro in the United States is approximately $1,000–$1,200 (Rs 86,000–Rs 1 lakh).

Eli Lilly has also launched a campaign to combat the stigma surrounding obesity and raise awareness of its health implications.

Meanwhile, Novo Nordisk, the Danish pharmaceutical company known for its weight loss drug Ozempic, has also begun an awareness campaign titled “Break the Partnership” on World Obesity Day. This campaign aims to educate the public on the connection between weight and diabetes, encouraging people to consult doctors about modern treatment options. Novo Nordisk has yet to announce the timeline for Ozempic’s launch in India.